Related Experiment Video

Updated: May 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K Arrington1, Eileen L Heinrich, Wendy Lee

  • 1Division of Surgical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. aarrington@coh.org.

International Journal of Molecular Sciences
|December 4, 2012
PubMed

Insights

KRAS mutations are common in colon cancer, impacting survival and treatment. This review explores KRAS history, its prognostic value, and predictive role in colorectal cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The RAS gene family, including KRAS, is crucial in cancer development.
  • KRAS is the most frequently altered RAS isoform, found in 17%-25% of all cancers.
  • KRAS mutations specifically occur in 30%-40% of colon cancers, correlating with aggressive disease.

Purpose of the Study:

  • To review the history and significance of KRAS in colorectal cancer.
  • To analyze the prognostic implications of KRAS mutations in colon cancer patients.
  • To evaluate the predictive value of KRAS mutations for targeted colorectal cancer therapies.

Main Methods:

  • Literature review of studies on KRAS gene.
  • Analysis of prognostic and predictive data related to KRAS mutations in colorectal cancer.
  • Examination of treatment resistance associated with KRAS alterations.

Main Results:

  • KRAS mutations are linked to poorer survival and increased tumor aggressiveness in colon cancer.
  • These mutations confer resistance to certain treatment strategies in colorectal cancer.
  • KRAS status is a key factor in determining patient prognosis and therapeutic options.

Conclusions:

  • KRAS is a critical oncogene in colorectal cancer, influencing patient outcomes.
  • Understanding KRAS mutation status is essential for personalized treatment strategies.
  • Further research into KRAS-targeted therapies holds promise for improving colorectal cancer management.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...